Show Summary Details
Page of

Oral anticoagulation 

Oral anticoagulation
Chapter:
Oral anticoagulation
Author(s):

Freek W. A. Verheugt

, Sam Schulman

, Andrea Rubboli

, Jonathan L. Halperin

, and Gregory Y. H. Lip

DOI:
10.1093/med/9780199665952.003.0003
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 09 August 2020

Oral anticoagulation (OAC) is indicated to prevent the occurrence and/or recurrence of arterial and venous thromboembolism. Oral anticoagulation is a complex treatment requiring appropriate indications and careful management. Vitamin K-antagonists (warfarin, acenocoumarol, phenprocoumon), and newer, non-vitamin K-antagonists direct inhibitors of thrombin (dabigatran) or of factor Xa (rivaroxaban, apixaban) are the oral anticoagulants currently available. Bleeding is the most frequent unwanted effect of oral anticoagulation, and may have important prognostic impact. Stratification of the individual risk of thromboembolism and bleeding is advised prior to starting oral anticoagulation to optimize the risk to benefit ratio.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.